These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 30368417)

  • 1. Combination of Crizotinib and Osimertinib or Erlotinib Might Overcome MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutated Adenocarcinoma.
    Giroux-Leprieur E; Dumenil C; Chinet T
    J Thorac Oncol; 2018 Nov; 13(11):e232-e234. PubMed ID: 30368417
    [No Abstract]   [Full Text] [Related]  

  • 2. A Novel CAV1-MET Fusion in SCLC Transformation Responds to Crizotinib and Osimertinib Treatment.
    Liu J; Li X; Peng J
    J Thorac Oncol; 2019 Jun; 14(6):e126-e128. PubMed ID: 31122565
    [No Abstract]   [Full Text] [Related]  

  • 3. Early-onset interstitial pneumonitis in a patient with advanced non-small cell lung cancer treated with crizotinib and osimertinib.
    Cheng Y; Yu Q; Xiong Y; Guo C; Nie L
    Thorac Cancer; 2021 Mar; 12(5):690-692. PubMed ID: 33438350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crizotinib plus erlotinib overcomes osimertinib resistance in a seriously-ill non-small cell lung cancer patient with acquired MET amplification.
    Zhao ZM; Wang SP; Sun L; Ji YX
    Chin Med J (Engl); 2020 Nov; 134(3):373-374. PubMed ID: 33186133
    [No Abstract]   [Full Text] [Related]  

  • 5. Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance
    Starrett JH; Guernet AA; Cuomo ME; Poels KE; van Alderwerelt van Rosenburgh IK; Nagelberg A; Farnsworth D; Price KS; Khan H; Ashtekar KD; Gaefele M; Ayeni D; Stewart TF; Kuhlmann A; Kaech SM; Unni AM; Homer R; Lockwood WW; Michor F; Goldberg SB; Lemmon MA; Smith PD; Cross DAE; Politi K
    Cancer Res; 2020 May; 80(10):2017-2030. PubMed ID: 32193290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression.
    Ou SI; Agarwal N; Ali SM
    Lung Cancer; 2016 Aug; 98():59-61. PubMed ID: 27393507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Durable response to EGFR tyrosine kinase inhibitors in a patient with non-small cell lung cancer harboring an EGFR kinase domain duplication.
    Hirokawa E; Watanabe S; Sakai K; Takeda M; Sato C; Takahama T; Nishio K; Nakagawa K
    Thorac Cancer; 2021 Aug; 12(16):2283-2287. PubMed ID: 34240806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tyrosine Kinase Inhibitors for Acute Respiratory Failure Because of Non-small-Cell Lung Cancer Involvement in the ICU.
    Tandjaoui-Lambiotte Y; Akrour Y; Gibelin A; Gonzalez F; Stoclin A; Moreau AS; Jaubert P; Oppenheimer A; Duchemann B; Gaudry S
    Chest; 2022 Jan; 161(1):284-287. PubMed ID: 34302842
    [No Abstract]   [Full Text] [Related]  

  • 9. Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer.
    Leighl NB; Karaseva N; Nakagawa K; Cho BC; Gray JE; Hovey T; Walding A; Rydén A; Novello S
    Eur J Cancer; 2020 Jan; 125():49-57. PubMed ID: 31838405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overall Survival with Osimertinib in Untreated,
    Ramalingam SS; Vansteenkiste J; Planchard D; Cho BC; Gray JE; Ohe Y; Zhou C; Reungwetwattana T; Cheng Y; Chewaskulyong B; Shah R; Cobo M; Lee KH; Cheema P; Tiseo M; John T; Lin MC; Imamura F; Kurata T; Todd A; Hodge R; Saggese M; Rukazenkov Y; Soria JC;
    N Engl J Med; 2020 Jan; 382(1):41-50. PubMed ID: 31751012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib.
    Li Y; Zang H; Qian G; Owonikoko TK; Ramalingam SR; Sun SY
    Cancer; 2020 Mar; 126(6):1339-1350. PubMed ID: 31821539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overall survival in stage IV EGFR mutation‑positive NSCLC: Comparing first‑, second‑ and third‑generation EGFR‑TKIs (Review).
    Vaid AK; Gupta A; Momi G
    Int J Oncol; 2021 Feb; 58(2):171-184. PubMed ID: 33491758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment.
    Shi P; Oh YT; Zhang G; Yao W; Yue P; Li Y; Kanteti R; Riehm J; Salgia R; Owonikoko TK; Ramalingam SS; Chen M; Sun SY
    Cancer Lett; 2016 Oct; 380(2):494-504. PubMed ID: 27450722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osimertinib Called "Home Run" for
    Cancer Discov; 2020 Jul; 10(7):896. PubMed ID: 32487567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the Efficacy of EGFR Tyrosine Kinase Inhibitors Erlotinib and Low-dose Osimertinib on a PC-9-GFP
    Katsuya Y; Miyake K; Higuchi T; Oshiro H; Sugisawa N; Singh SR; Goto Y; Zhao M; Hoffman RM
    In Vivo; 2020; 34(3):1027-1030. PubMed ID: 32354888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung cancer patients.
    Reis R; Labat L; Allard M; Boudou-Rouquette P; Chapron J; Bellesoeur A; Thomas-Schoemann A; Arrondeau J; Giraud F; Alexandre J; Vidal M; Goldwasser F; Blanchet B
    J Pharm Biomed Anal; 2018 Sep; 158():174-183. PubMed ID: 29883880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study.
    Miyawaki T; Kenmotsu H; Kodama H; Nishioka N; Miyawaki E; Mamesaya N; Kobayashi H; Omori S; Ko R; Wakuda K; Ono A; Naito T; Murakami H; Mori K; Harada H; Endo M; Takahashi K; Takahashi T
    BMC Cancer; 2021 Nov; 21(1):1247. PubMed ID: 34798865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world data on treatment outcomes in
    Dal Maso A; Lorenzi M; Ferro A; Pilotto S; Cecere F; Follador A; Polo V; Del Conte A; Sartori G; Giavarra M; Scattolin D; Indraccolo S; Frega S; De Maglio G; Menis J; Bonanno L; Calabrese F; Guarneri V; Conte P; Pasello G
    Future Oncol; 2021 Jul; 17(19):2513-2527. PubMed ID: 33988036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study.
    Cheng Y; He Y; Li W; Zhang HL; Zhou Q; Wang B; Liu C; Walding A; Saggese M; Huang X; Fan M; Wang J; Ramalingam SS
    Target Oncol; 2021 Mar; 16(2):165-176. PubMed ID: 33544337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Network meta analysis of first-line therapy for advanced EGFR mutation positive non-small-cell lung cancer: updated overall survival.
    Farris M; Larkin-Kaiser KA; Scory T; Boyne D; Wilner KD; Pastel M; Cappelleri JC; Ivanova JI
    Future Oncol; 2020 Dec; 16(36):3107-3116. PubMed ID: 32869649
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.